ReviewDiagnostics (Basel, Switzerland)2026
From Detection to Surveillance: The Evolving Role of Micro-Ultrasound in Prostate Cancer.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-resolution micro-ultrasound (microUS) is a 29 MHz imaging modality that allows visualisation of prostatic ductal architecture at 70 µm resolution, enabling real-time recognition of architectural disruption associated with clinically significant prostate cancer (csPCa). This review summarises the current evidence for microUS in the diagnosis and management of prostate cancer, with emphasis on developments since the pivotal OPTIMUM phase-3 randomised controlled trial. OPTIMUM provided level 1 evidence for microUS-guided biopsy as non-inferior to MRI-guided biopsy for csPCa detection. We examine the PRI-MUS risk identification protocol, the pre- and post-OPTIMUM evidence base, biopsy targeting and core number, inter-observer reliability and the learning curve, and emerging applications in active surveillance, restaging biopsy, local staging and tumour characterisation, and post-treatment surveillance for local recurrence. We also review the growing body of work on artificial intelligence-enhanced microUS, alongside workflow, cost, and environmental considerations. Whilst inter-reader variability and the learning curve remain barriers, microUS offers comparable sensitivity to multiparametric MRI with practical advantages in cost, accessibility, and workflow. In our view, microUS warrants acceptance as a primary imaging modality for the work-up of suspected prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.